NCT02368184

Brief Summary

The purpose of this study is to obtain observational data allowing for the preliminary assessment of the utility of a noninvasive physiologic monitor for monitoring of patients with congestive heart failure.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Feb 2015

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2015

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

February 9, 2015

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 20, 2015

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2016

Completed
Last Updated

May 25, 2016

Status Verified

May 1, 2016

Enrollment Period

1.2 years

First QC Date

February 9, 2015

Last Update Submit

May 23, 2016

Conditions

Keywords

noninvasive physiologic monitoringacute decompensated heart failure (ADHF)

Outcome Measures

Primary Outcomes (1)

  • Track physiologic parameters among patients with ADHF and explore predictive algorithms to allow for early ID of patients at risk of ADHF.

    * To track on a daily basis important physiologic parameters among patients with a primary diagnosis of acute decompensated heart failure (ADHF) beginning at the time of their hospitalization and then continued for up to 60 days after discharge, in order to better understand their inter- and intra- individual variability and compare this to standard monitoring including daily weights. * To explore the development of predictive algorithms to allow for the early identification of patients at risk of acute decompensation and/or HF hospitalization.

    65 days

Secondary Outcomes (1)

  • Compare transthoracic impedance in individuals who already have a Medtronic implanted device with OptiVol technology.

    65 days

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population will be made up of adult men and women admitted to the hospital with a primary clinical diagnosis of acute decompensated heart failure. A convenience sample of 25 individuals meeting the following Inclusion criteria and have no Exclusion criteria will be enrolled.

You may qualify if:

  • Adults over age 18
  • Have wireless internet access within their homes.
  • Acute hospitalization with a primary diagnosis of acute decompensated heart failure (ADHF) diagnosed on the basis of all of the following:
  • Symptoms:
  • Onset or worsening of dyspnea within the past 2 weeks
  • Physical exam (at least 1 present):
  • Rales/ Crackles on auscultation
  • Elevated JVP \> 8 cmH2O
  • Weight gain
  • LE edema
  • Diagnostic imaging/ labs (at least 1 present):
  • Evidence of pulmonary congestion or edema on chest X-ray/ chest CT
  • Elevated NT-pro-BNP (age-adjusted) (\>1000)
  • Patients of particular interest will be those who already have a Medtronic Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy device with the OptiVol feature that tracks transthoracic impedance.

You may not qualify if:

  • Allergy to ECG electrodes
  • Psychological or social situation that would make the study difficult for the patient
  • Inability to consent
  • Pregnant women
  • Pneumonia - currently, or within the past 30 days
  • Non-cardiogenic pulmonary edema (e.g. ARDS)
  • Interstitial lung disease
  • End-stage renal disease and on hemodialysis
  • For any reason unable to wear or place the CoVa™ device, e.g. pectus excavatum, fragile skin, severe arthritis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Scripps Health

San Diego, California, 92037, United States

Location

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Steven Steinhuble, MD

    Scripps Translational Science Institute

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 9, 2015

First Posted

February 20, 2015

Study Start

February 1, 2015

Primary Completion

May 1, 2016

Study Completion

May 1, 2016

Last Updated

May 25, 2016

Record last verified: 2016-05

Data Sharing

IPD Sharing
Will not share

Locations